Item 8.01 Other Events.
On August 24, 2022, ILiAD Biotechnologies LLC ("ILiAD") completed a private
financing of $42,836,000 of Class D units, of which a multi-national
pharmaceutical company invested $30,000,000 (the "Financing"). As part of the
Financing, Network-1 Technologies, Inc. (the "Company") invested $1,000,000 and
its convertible note in the principal amount of $1,000,000 plus accrued
interest, in accordance with its terms, converted into units of ILiAD. Since
December 2018, the Company has invested an aggregate of approximately $7,000,000
in ILiAD. ILiAD is a clinical stage biotechnology company dedicated to the
prevention and treatment of human disease caused by Bordetella pertussis and is
developing technologies that focus on validating its proprietary intranasal
vaccine (BPZE1) for the prevention of pertussis (whooping cough).
-2-
© Edgar Online, source Glimpses
NETWORK-1 TECHNOLOGIES, INC. 
